Screening for Age-Related Skeletal Muscle Dysfunction (ARMS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02277236 |
Recruitment Status :
Active, not recruiting
First Posted : October 28, 2014
Last Update Posted : December 19, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Sarcopenia | Radiation: DXA scanning Radiation: CT imaging |
The primary goals of this project are to: 1) develop and validate a rapid, portable, cost-effective, screening method for sarcopenia using diagnostic ultrasound (US), and 2) determine if the US screening method provides viable estimates of intramuscular adipose tissue (IMAT) since muscle tissue age-related changes in muscle composition are associated with low muscle torque and metabolic dysfunction. The proposed US screening method may be used as a proxy measure of LBM and provide estimates of skeletal muscle composition that relate to IMAT, lipid metabolism, insulin homeostasis and inflammation - important factors that may impact impaired mobility and metabolic dysfunction in older African American Veterans.
Aim 1:
Determine the association between a proxy measure of LBM obtained via portable, diagnostic, musculoskeletal US and LBM as determined by dual energy X-ray absorptiometry (DXA).
The working hypothesis is that a 6-muscle model of LBM derived from US and DXA LBM values will exhibit a significant positive association and attain a coefficient of determination > .80.
Aim 2:
Determine the association between US echointensity features and IMAT as determined by CT scan.
US echointensity values will be acquired from the rectus femoris and analyzed to determine the association with IMAT. The working hypothesis is that higher echointensity values measured with grayscale analysis will be negatively associated with the Hounsfield units obtained from the CT scan (p < .05).
Aim 3:
Examine the association between US echointensity values and biologic factors that impair insulin sensitivity.
Excessive IMAT and intra-myocellular triglyceride levels result in increased levels of biologic factors such as inflammatory cytokines (TNF-α and IL-6), which may affect insulin sensitivity. The investigators hypothesis is that proxy measures of IMAT via echointensity values will be positively associated with biomarkers of inflammation and insulin homeostasis.
Study Type : | Observational |
Actual Enrollment : | 30 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Creating a Model of Proactive Geriatric Care Within VISN 5: Screening for Age-Related Skeletal Muscle Dysfunction at the Washington DC VA Medical Center |
Study Start Date : | October 2014 |
Actual Primary Completion Date : | September 2017 |
Estimated Study Completion Date : | August 2020 |

Group/Cohort | Intervention/treatment |
---|---|
Younger Veterans
Male Veterans, 45-64.9 years of age. (Exposures include DXA scanning and CT imaging.)
|
Radiation: DXA scanning
Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
Other Name: Radiograph, x-rays Radiation: CT imaging Exposure: Estimates of intramuscular adipose tissue (IMAT) will be obtained with CT imaging. This measure will be restricted to a single leg (dominant side) in the mid-femur region, using a single 10mm axial image slice (120 kVp, 200 to 250 mA).
Other Name: CAT scan |
Young-Old Veterans
Male Veterans, 65-84.9 years of age. (Exposures include DXA scanning and CT imaging.)
|
Radiation: DXA scanning
Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
Other Name: Radiograph, x-rays Radiation: CT imaging Exposure: Estimates of intramuscular adipose tissue (IMAT) will be obtained with CT imaging. This measure will be restricted to a single leg (dominant side) in the mid-femur region, using a single 10mm axial image slice (120 kVp, 200 to 250 mA).
Other Name: CAT scan |
- Sonographic Lean Body Mass [ Time Frame: 1 day ]US estimates of aggregate regional LBM (muscle thickness, cm), will be assessed using B-mode diagnostic US with a 13-6 MHz linear array transducer for morphology measures at 6 axial and appendicular sites. The following sites will be assessed: the midpoint of the upper trapezius, upper pectoralis major, lateral deltoid, brachioradialis, rectus femoris, and tibialis anterior.
- Metabolic status [ Time Frame: 1 day ]A blood sample (60 cc) will be obtained after an 8-hour overnight fast: glucose and insulin levels will be assessed before and during a standard (75 g) 2 hour oral glucose tolerance test. Other laboratory values such as a standard lipid profile and selected cytokines (IL-6), will also be measured.
- DXA lean body mass [ Time Frame: At time of assessment ]Participants will undergo dual energy X-ray absorptiometry (DXA) scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total LBM, and body fat percentage (BF%).
- Intramuscular adipose tissue assessment [ Time Frame: 1 day ]Estimates of intramuscular adipose tissue (IMAT) will be obtained with CT imaging. A single, unilateral 10mm axial image slice (120 kVp, 200 to 250 mA) of the thigh will be obtained at the midfemur region (corresponding to the ultrasound scanning site).
- Strength assessment [ Time Frame: 1 day ]Grip strength will be assessed bilaterally; isokinetic knee extension/flexion torques will be obtained bilaterally using the Biodex System 4. Peak concentric torque (at 60º/s and 180º/s) will be obtained in a randomized fashion with subject positioning and stabilization per the Biodex Operations Manual.
- Functional assessment [ Time Frame: 1 day ]A standardized timed sit-to-stand test will be conducted (5 repetitions); 6m walking speed (habitual and fast gait) will be recorded; the Physical Performance Test (PPT-7), a functional battery validated for use with older adults, will be used in this study to assess the activities of daily living of the participants.
- Physical activity questionnaire [ Time Frame: 1 day ]Participants will also complete the International Physical Activity Questionnaire (IPAQ) to obtain an estimate of their customary activity and formal exercise.
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 45 Years to 85 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria: You are eligible to participate if:
- You are registered to receive healthcare at the Washington DC VAMC through the Geriatrics Extended Care Service and/or Primary Care Service.
- You are a male.
- You are between the ages of 45 - 85 years.
-
Must be able to stand comfortably for 10 minutes and walk a short distance (use of assistive devices are acceptable).
-
Exclusion Criteria: You are not eligible to participate if:
- You have uncontrolled hypertension.
- Body Mass Index (BMI) <18.5 or >32.5.
- Musculoskeletal conditions that would stop you from performing the physical assessment test.
- Muscle weakness due to neurological disease or injury (such as stroke or spinal cord injury).
- Moderate to severe sepsis (blood infection) or edema (such as swelling of a limb).
- Currently prescribed medications that affect glucose or insulin.
- Uncontrolled cardiovascular disease.
- Hospitalization over the last three months.
-
Diagnosis of diabetes.
-

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02277236
United States, District of Columbia | |
Washington DC VA Medical Center | |
Washington, District of Columbia, United States, 20422 |
Principal Investigator: | Michael Harris-Love, MPT, DSc | Washington DC VA Medical Center |
Responsible Party: | Michael Harris-Love, Principal Investigator, Washington D.C. Veterans Affairs Medical Center |
ClinicalTrials.gov Identifier: | NCT02277236 |
Other Study ID Numbers: |
MIRB01671 |
First Posted: | October 28, 2014 Key Record Dates |
Last Update Posted: | December 19, 2019 |
Last Verified: | December 2019 |
sarcopenia aging insulin resistance screening |
Sarcopenia Muscular Atrophy Neuromuscular Manifestations Neurologic Manifestations |
Nervous System Diseases Atrophy Pathological Conditions, Anatomical |